Render Target: STATIC
Render Timestamp: 2025-03-20T10:21:09.554Z
Commit: 779953b12a5930618aae6aca7c87fb286faeb1d7
XML generation date: 2025-03-07 13:20:31.493
Product last modified at: 2025-03-11T08:00:13.966Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

CCR4 (F9A9K) Rabbit mAb #59945

Filter:
  • WB
  • IHC

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 40-80
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IHC-Immunohistochemistry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunohistochemistry (Paraffin) 1:100 - 1:400

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    CCR4 (F9A9K) Rabbit mAb recognizes endogenous levels of total CCR4 protein. This antibody detects a 15-20 kDa protein of unknown identity in some cell lines.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human CCR4 protein.

    Background

    C-C chemokine receptor type 4 (CCR4) is a chemokine receptor that is primarily expressed in T cells, specifically in Th2, Th17, and Treg subsets (1). Like other chemokine receptors, CCR4 is a G protein-coupled receptor (GPCR) that contains seven transmembrane domains (2). CCR4 selectively binds with the chemokine ligands CCL17, also known as thymus and activation-related chemokine (TARC), and CCL22, also known as macrophage-derived chemokine (MDC). CCL17/TARC functions as a chemoattractant for CCR4-expressing T cells and is associated with type 2 immune responses (3,4). CCL22/MDC is expressed by macrophages and dendritic cells and also functions as a chemoattractant with dominant binding to CCR4 compared with CCL17/TARC (5-7). Elevated CCR4 expression has been implicated in various allergic diseases, such as asthma and dermatitis (8,9). It has also been implicated in several hematological malignancies, including acute myeloid leukemia (AML), acute T cell leukemia/lymphoma (ATLL), and cutaneous T cell lymphoma (CTLL) (1,10). The humanized anti-CCR4 monoclonal antibody mogamulizumab has been approved for the treatment of patients with relapsed ATLL (11).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.